Predictive Value of the Uric Acid/Albumin Ratio and Lactate in Sepsis Patients

Starting soon

Conditions studied: Sepsis-Related Mortality, Acute Kidney Injury

In brief

Sepsis is a life-threatening condition characterized by organ dysfunction resulting from a dysregulated host response to infection and remains a leading cause of morbidity and mortality in intensive care units. Early identification of patients at high risk for adverse outcomes is essential for timely intervention and improved prognosis. This prospective, single-center, non-interventional study aims to evaluate the predictive value of the combined use of the blood uric acid/albumin ratio (UAR) and serum lactate levels in patients aged 65 years and older who are admitted to the intensive care unit with a diagnosis of sepsis according to SEPSIS-3 criteria. Patients without acute kidney injury at admission and with at least 24 hours of intensive care follow-up will be included. The primary outcome is the development of acute kidney injury within the first 7 days of ICU admission according to KDIGO criteria. Secondary outcomes include vasopressor requirement during ICU stay, changes in serum lactate levels over the first 24 hours, and 28-day mortality. The study seeks to determine whether the combination of UAR and lactate levels can serve as an easily accessible and clinically applicable biomarker to predict adverse outcomes and support prognostic assessment and treatment strategies in sepsis patients.

Key facts

Study ID: NCT07332715
Run by: Istinye University
People needed: 80
Starts: 2026-01-15
Expected to finish: 2026-05-31
Last updated by the study team: 2026-01-13

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients aged 65 years and older
Diagnosis of sepsis according to SEPSIS-3 criteria
Admission to the intensive care unit
No acute kidney injury at admission according to KDIGO classification
Measurement of serum uric acid, albumin, and lactate levels at ICU admission
SOFA score calculated at ICU admission
ICU follow-up of at least 24 hours

You may not qualify if…

Age under 65 years
Uncompensated or decompensated chronic liver disease (e.g., Child-Pugh class C)
Chronic kidney disease stage 4 or 5 (eGFR <30 mL/min/1.73 m²)
Presence of acute kidney injury at admission according to KDIGO criteria
Active malignancy or receipt of active cancer treatment within the last 6 months
Missing or incomplete clinical/laboratory data
ICU follow-up less than 24 hours

Where it is running

Istinye Üniversity — Istanbul, Merkez Mahallesi, Turkey (Türkiye)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.